Emerging drugs for eosinophilic esophagitis

Robert D. Pesek, Sandeep Gupta

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Introduction: Eosinophilic esophagitis (EoE) is rare but incidence and prevalence is increasing. EoE is characterized by eosinophilic inflammation of the esophagus causing gastrointestinal symptoms such as abdominal pain, vomiting, reflux, dysphagia, and food impactions. If untreated, remodeling and fibrosis of the esophagus can occur and stricture formation may result. Current treatment options are limited to food-restriction diets or medications including proton pump inhibitors (PPIs) or swallowed corticosteroids. Significant progress has been made in understanding the underlying mechanisms of EoE allowing for development of drugs that target specific points in EoE pathways. Investigation of these drugs is early with few controlled studies, but many show promise as future treatments. Areas covered: This review will provide an up to date discussion of current therapies and investigational drugs for EoE. Articles used in this review were retrieved from PubMed. Ongoing or completed clinical trials were obtained through clinicaltrials.gov and review of the PharmaProjects database. Expert Opinion: Multiple therapeutic targets have been identified and several have shown efficacy. Work is needed to define appropriate trial outcome measures. Collaboration between government agencies, patient advocacy groups, and investigator-led consortia is critical for completing new clinical trials which should pave the way for new therapies in clinical practice.

Original languageEnglish (US)
Pages (from-to)173-183
Number of pages11
JournalExpert Opinion on Emerging Drugs
Volume23
Issue number2
DOIs
StatePublished - Apr 3 2018
Externally publishedYes

Fingerprint

Eosinophilic Esophagitis
Pharmaceutical Preparations
Esophagus
Clinical Trials
Investigational Drugs
Patient Advocacy
Government Agencies
Therapeutics
Food
Proton Pump Inhibitors
Expert Testimony
Deglutition Disorders
PubMed
Abdominal Pain
Vomiting
Adrenal Cortex Hormones
Pathologic Constriction
Fibrosis
Research Personnel
Outcome Assessment (Health Care)

Keywords

  • biologics
  • dupilumab
  • Eosinophilic esophagitis (EoE)
  • food-elimination diet
  • mepolizumab
  • proton pump inhibitor (PPI)
  • reslizumab
  • swallowed corticosteroids

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Emerging drugs for eosinophilic esophagitis. / Pesek, Robert D.; Gupta, Sandeep.

In: Expert Opinion on Emerging Drugs, Vol. 23, No. 2, 03.04.2018, p. 173-183.

Research output: Contribution to journalReview article

Pesek, Robert D. ; Gupta, Sandeep. / Emerging drugs for eosinophilic esophagitis. In: Expert Opinion on Emerging Drugs. 2018 ; Vol. 23, No. 2. pp. 173-183.
@article{c76a914d100342159c3507d6c658f6d8,
title = "Emerging drugs for eosinophilic esophagitis",
abstract = "Introduction: Eosinophilic esophagitis (EoE) is rare but incidence and prevalence is increasing. EoE is characterized by eosinophilic inflammation of the esophagus causing gastrointestinal symptoms such as abdominal pain, vomiting, reflux, dysphagia, and food impactions. If untreated, remodeling and fibrosis of the esophagus can occur and stricture formation may result. Current treatment options are limited to food-restriction diets or medications including proton pump inhibitors (PPIs) or swallowed corticosteroids. Significant progress has been made in understanding the underlying mechanisms of EoE allowing for development of drugs that target specific points in EoE pathways. Investigation of these drugs is early with few controlled studies, but many show promise as future treatments. Areas covered: This review will provide an up to date discussion of current therapies and investigational drugs for EoE. Articles used in this review were retrieved from PubMed. Ongoing or completed clinical trials were obtained through clinicaltrials.gov and review of the PharmaProjects database. Expert Opinion: Multiple therapeutic targets have been identified and several have shown efficacy. Work is needed to define appropriate trial outcome measures. Collaboration between government agencies, patient advocacy groups, and investigator-led consortia is critical for completing new clinical trials which should pave the way for new therapies in clinical practice.",
keywords = "biologics, dupilumab, Eosinophilic esophagitis (EoE), food-elimination diet, mepolizumab, proton pump inhibitor (PPI), reslizumab, swallowed corticosteroids",
author = "Pesek, {Robert D.} and Sandeep Gupta",
year = "2018",
month = "4",
day = "3",
doi = "10.1080/14728214.2018.1483335",
language = "English (US)",
volume = "23",
pages = "173--183",
journal = "Expert Opinion on Emerging Drugs",
issn = "1472-8214",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Emerging drugs for eosinophilic esophagitis

AU - Pesek, Robert D.

AU - Gupta, Sandeep

PY - 2018/4/3

Y1 - 2018/4/3

N2 - Introduction: Eosinophilic esophagitis (EoE) is rare but incidence and prevalence is increasing. EoE is characterized by eosinophilic inflammation of the esophagus causing gastrointestinal symptoms such as abdominal pain, vomiting, reflux, dysphagia, and food impactions. If untreated, remodeling and fibrosis of the esophagus can occur and stricture formation may result. Current treatment options are limited to food-restriction diets or medications including proton pump inhibitors (PPIs) or swallowed corticosteroids. Significant progress has been made in understanding the underlying mechanisms of EoE allowing for development of drugs that target specific points in EoE pathways. Investigation of these drugs is early with few controlled studies, but many show promise as future treatments. Areas covered: This review will provide an up to date discussion of current therapies and investigational drugs for EoE. Articles used in this review were retrieved from PubMed. Ongoing or completed clinical trials were obtained through clinicaltrials.gov and review of the PharmaProjects database. Expert Opinion: Multiple therapeutic targets have been identified and several have shown efficacy. Work is needed to define appropriate trial outcome measures. Collaboration between government agencies, patient advocacy groups, and investigator-led consortia is critical for completing new clinical trials which should pave the way for new therapies in clinical practice.

AB - Introduction: Eosinophilic esophagitis (EoE) is rare but incidence and prevalence is increasing. EoE is characterized by eosinophilic inflammation of the esophagus causing gastrointestinal symptoms such as abdominal pain, vomiting, reflux, dysphagia, and food impactions. If untreated, remodeling and fibrosis of the esophagus can occur and stricture formation may result. Current treatment options are limited to food-restriction diets or medications including proton pump inhibitors (PPIs) or swallowed corticosteroids. Significant progress has been made in understanding the underlying mechanisms of EoE allowing for development of drugs that target specific points in EoE pathways. Investigation of these drugs is early with few controlled studies, but many show promise as future treatments. Areas covered: This review will provide an up to date discussion of current therapies and investigational drugs for EoE. Articles used in this review were retrieved from PubMed. Ongoing or completed clinical trials were obtained through clinicaltrials.gov and review of the PharmaProjects database. Expert Opinion: Multiple therapeutic targets have been identified and several have shown efficacy. Work is needed to define appropriate trial outcome measures. Collaboration between government agencies, patient advocacy groups, and investigator-led consortia is critical for completing new clinical trials which should pave the way for new therapies in clinical practice.

KW - biologics

KW - dupilumab

KW - Eosinophilic esophagitis (EoE)

KW - food-elimination diet

KW - mepolizumab

KW - proton pump inhibitor (PPI)

KW - reslizumab

KW - swallowed corticosteroids

UR - http://www.scopus.com/inward/record.url?scp=85048493097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048493097&partnerID=8YFLogxK

U2 - 10.1080/14728214.2018.1483335

DO - 10.1080/14728214.2018.1483335

M3 - Review article

C2 - 29848130

AN - SCOPUS:85048493097

VL - 23

SP - 173

EP - 183

JO - Expert Opinion on Emerging Drugs

JF - Expert Opinion on Emerging Drugs

SN - 1472-8214

IS - 2

ER -